drugset / Trial / NCT05568225
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
Timeline
- Start
- 2022-11-15
- Primary completion
- 2024-07-15
- Completion
- 2024-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etavopivat | Small molecule | 400 mg | — |
Indications
No indication recorded.